deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT01335399

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma (ELOQUENT - 1)

A Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Subjects With Previously Untreated Multiple Myeloma

Sponsor: AbbVie

Conditions Multiple Myeloma
Interventions Dexamethasone Elotuzumab (BMS-901608; HuLuc63) Lenalidomide
Updated 18 times since 2017 Last updated: Sep 2, 2022 Started: Aug 4, 2011 Primary completion: Oct 1, 2019 Completion: Sep 3, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Multiple Myeloma and is currently completed. AbbVie leads this study, which shows 18 recorded versions since 2011 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jun 2017 · 4 months · monthly snapshot~Jun 2017 – ~Dec 2017 · 6 months · monthly snapshot~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Nov 2018 · 3 months · monthly snapshot~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshot~Dec 2018 – ~Sep 2019 · 9 months · monthly snapshot~Sep 2019 – ~Mar 2020 · 6 months · monthly snapshot~Mar 2020 – ~Nov 2020 · 8 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Mar 2022 · 14 months · monthly snapshot~Mar 2022 – ~Sep 2022 · 6 months · monthly snapshot~Sep 2022 – ~Oct 2022 · 30 days · monthly snapshot~Oct 2022 – ~Jul 2024 · 21 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 9 months · monthly snapshot

Change History

18 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Oct 2022 — Jul 2024 [monthly]

    Completed PHASE3

  5. Sep 2022 — Oct 2022 [monthly]

    Completed PHASE3

▶ Show 13 earlier versions

  1. Mar 2022 — Sep 2022 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  2. Jan 2021 — Mar 2022 [monthly]

    Active Not Recruiting PHASE3

  3. Nov 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE3

  4. Mar 2020 — Nov 2020 [monthly]

    Active Not Recruiting PHASE3

  5. Sep 2019 — Mar 2020 [monthly]

    Active Not Recruiting PHASE3

  6. Dec 2018 — Sep 2019 [monthly]

    Active Not Recruiting PHASE3

  7. Nov 2018 — Dec 2018 [monthly]

    Active Not Recruiting PHASE3

  8. Aug 2018 — Nov 2018 [monthly]

    Active Not Recruiting PHASE3

  9. Jun 2018 — Aug 2018 [monthly]

    Active Not Recruiting PHASE3

  10. Dec 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE3

  11. Jun 2017 — Dec 2017 [monthly]

    Active Not Recruiting PHASE3

  12. Feb 2017 — Jun 2017 [monthly]

    Active Not Recruiting PHASE3

  13. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE3

    First recorded

Aug 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AbbVie
  • Bristol-Myers Squibb
Data source: Bristol-Myers Squibb

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Adelaide, Australia , Afula, Israel , Ancona, Italy , Ankara, Turkey (Türkiye) , Aschaffenburg, Germany , Ashkelon, Israel , Athens, Greece , Atlanta, United States , Badalona-barcelona, Spain , Bakersfield, United States and 185 more locations